The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index; 11 of the 11 sources its claims cite were checked for support.
Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression
Open accessAbstract
Recent pairwise meta-analysis including only double-blind, randomized placebo-controlled trials (DBRPCTs) with an enrichment design in which individuals with MDD were stabilized on the antidepressant of interest during the open-label study and then randomized to receive the same antidepressant or a placebo was conducted [ 1 ]. The meta-analysis reported that the antidepressant maintenance group had a significantly lower relapse rate than the antidepressant discontinuation group ( K = 40, n = 8890) [ 1 ]. A subgroup meta-analysis revealed similar relapse rates for maintenance periods of 6 months and 1 year [ 1 ]. Therefore, the authors recommended antidepressant maintenance treatment for at least 6 months after remission to prevent relapse [ 1 ]. A subsequent DBRPCT found relapse rates for an antidepressant maintenance group and a discontinuation group at 26 weeks of 32 and 56% (24% difference), respectively; and relapse rates at 39 weeks of 40 and 69% (29% difference), respectively [ 2 ]. This means there was a 5% difference in relapse rates between the two groups from 26 to 39 weeks. Thus, the differences in relapse rates between individuals with MDD who continued antidepressants that were effective during acute treatment and those who discontinued the antidepressants are still unclear. Trends in the magnitude of the benefit of medication maintenance over time are important in determining how long individuals with MDD should continue taking antidepressants. While the meta-analysis described above was conducted using the relapse rate at the endpoint of each DBRPCT for individuals with MDD including general adults, children and adolescents or older individuals (range of study duration: 14–100 weeks) [ 1 ], the current systematic review and pairwise meta-analysis included DBRPCTs with adult participants only and compared relapse rates at matched observation time points (i.e., 3, 6 [primary outcome], 9, 12, 15, and 18 months) between discontinuation and maintenance groups to more accurately determine the temporal relapse trend.
Overview
CoChat Summary
TL;DR
In adults with major depressive disorder stabilized on antidepressants, maintenance treatment was associated with lower relapse than discontinuation across matched time points, with benefit appearing greater at 15–18 months though based on few studies. Meta-regression identified average age as the only moderator associated with relapse rates in both groups, with older adults having lower relapse rates but larger treatment effect sizes.
Key findings
- Across 35 double-blind randomized placebo-controlled trials (DBRPCTs) with 9442 adults with MDD (68% female; mean age 43.5 years), risk ratios for relapse at 3, 6, 9, and 12 months were similar, but the number needed to treat to benefit slightly decreased over time; relapse rates increased faster in the discontinuation group than in the maintenance group.
- The effect of antidepressants on relapse prevention was greater at 15 and 18 months than at 12 months or less, but few studies reported 15- and 18-month relapse rates, so these results might not be robust; the authors suggest maintenance treatment for 18 months (or at least 12 months).
- The maintenance group had a significantly lower all-cause discontinuation rate than the discontinuation group, but no significant difference was observed between groups in discontinuation due to adverse events.
- Meta-regression found effect size correlated with average age, total number of participants, dosing schedule, drug class, and publication year; only average age was associated with relapse rates in both the maintenance and discontinuation groups, with lower relapse rates in older than younger adults, and studies including older adults had greater effect sizes. Multivariate analysis confirmed these results.
Methods
- Systematic review and pairwise meta-analysis of DBRPCTs in adults with MDD, comparing relapse rates at matched observation time points: 3, 6 (primary outcome), 9, 12, 15, and 18 months; conducted per PRISMA and registered with the Open Science Framework.
- Included 35 DBRPCTs with 9442 adults with MDD; mean study duration was 41.9 ± 17.2 weeks; no studies had high risk of bias in at least one domain of the Risk of Bias 2 tool.
- Random-effects model was used; risk ratios with 95% confidence intervals were calculated; heterogeneity assessed with I²; single-group summary meta-analysis estimated relapse rates in both groups; NNTB estimated when pairwise differences were significant; meta-regression examined participant, treatment, and study-design moderators; analyses used Comprehensive Meta-Analysis version 3.
Limitations
- Stated: the study had several limitations presented in the Supplementary text, including a significant publication bias for the primary outcome.
- Stated: data on relapse rates at time points longer than 18 months were insufficient, so it remains unclear whether a longer period of antidepressant treatment is necessary.
- Stated/evident: the 15- and 18-month findings were based on a small number of studies and might not be robust; reasons for associations between effect size and moderators other than average age could not be identified because those moderators were not associated with relapse rates in both treatment groups.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
7 Valid · 2 Not valid · 0 Not checked · 23 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“and relapse rates at 39 weeks of 40 and 69% (29% difference), respectively [2].”
What the sources say
- Disputedcites [2] Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, et al. Maintenance or discontinuation of antidepressants in primary care. N. Engl J Med. 2021;385:1257–67. sourceExperimental — accuracy not yet measured
The Primary Outcome section reports relapse in 39% of the maintenance group and 56% of the discontinuation group over 52 weeks—a 17-percentage-point difference. It does not report the claimed 40% and 69% rates or a 29-point difference at 39 weeks. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“we found a significantly lower all-cause discontinuation rate (Fig. S9) in the maintenance group than in the discontinuation group”
What the sources say
- Supportedcites [1] Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26:118–33. source
The Results section (‘Relapse, acceptability, and tolerability at study endpoint’; page not available) reports an all-cause dropout measure of 43.3% with antidepressant continuation versus 58.2% with placebo discontinuation. The difference was statistically significant (pooled OR 0.47, p < 0.00001). (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A subsequent DBRPCT found relapse rates for an antidepressant maintenance group and a discontinuation group at 26 weeks of 32 and 56% (24% difference), respectively”
What the sources say
- Partly supportedcites [2] Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, et al. Maintenance or discontinuation of antidepressants in primary care. N. Engl J Med. 2021;385:1257–67. sourceExperimental — accuracy not yet measured
The Primary Outcome section reports more relapses in the discontinuation group, including the cited 56%, but that figure is for 52 weeks. It reports 39%, not 32%, for the maintenance group at 52 weeks; the cited 26-week rates and 24-point difference are not reported in the retrieved passages. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This means there was a 5% difference in relapse rates between the two groups from 26 to 39 weeks.”
What the sources say
- Partly supportedcites [2] Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, et al. Maintenance or discontinuation of antidepressants in primary care. N. Engl J Med. 2021;385:1257–67. sourceExperimental — accuracy not yet measured
The Primary Outcome section reports higher relapse in the discontinuation group than in the maintenance group: 56% versus 39% over 52 weeks. It does not report a 5% between-group difference specifically from 26 to 39 weeks; the 52-week figures cannot establish that interval-specific claim. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A subgroup meta-analysis revealed similar relapse rates for maintenance periods of 6 months and 1 year [1].”
What the sources say
- Supportedcites [1] Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26:118–33. source
The Results subsection on meta-regression and subgroup analyses reports similar relapse-rate differences between antidepressant and placebo groups in studies lasting 6 months and over 1 year. The Discussion also states that relapse rates remained unchanged from 6 months to over 1 year in both groups. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
17 more claims
Create a free account to see all 32 claims and every source verdict.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 4
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“This pairwise meta-analysis used a random-effects model [6].”
MethodCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322 · cited 1×
“Other recent meta-analyses for acute depression reported a correlation between antidepressant dosage or the type of antidepressant and efficacy [3, 4].”
ResultMaintenance or Discontinuation of Antidepressants in Primary Care
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106356 · Cited by 192 · cited 1×
“A subsequent DBRPCT found relapse rates for an antidepressant maintenance group and a discontinuation group at 26 weeks of 32 and 56% (24% difference), respectively; and relapse rates at 39 weeks of 40 and 69% (29% difference), respectively [2].”
BackgroundKato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152 · cited 6×
“While the meta-analysis described above was conducted using the relapse rate at the endpoint of each DBRPCT for individuals with MDD including general adults, children and adolescents or older individuals (range of study duration: 14–100 weeks) [1], the current systematic review and pairwise meta-analysis included DBR…”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., et al. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241245384 · Cited by 369
Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis
Kishi, T., Ikuta, T., Sakuma, K., Hatano, M., Matsuda, Y., Wilkening, J., Goya-Maldonado, R., Tik, M., Williams, N. R., Kito, S., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02630-5 · Cited by 74
Self-citationFagiolini, A. M., Cardoner, N., Pırıldar, Ş., Ittsakul, P., Ng, B., Duailibi, K., & Hindy, N. E. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2242264 · Cited by 22
“Moreover, since treatments prescribed for an acute depressive episode are typically continued into maintenance treatment, it is important to also assess the treatment’s effectiveness and suitability for the maintenance phase [57,58].”
Antidepressant Discontinuation Syndrome
Kim, S. H., Kim, Y. S., & Kang, U. G. (2024) · 신경정신의학 · doi:10.4306/jknpa.2024.63.2.104 · Cited by 12
Matsuda, Y., Sakuma, K., Kishi, T., Esaki, K., Kito, S., Shigeta, M., & Iwata, N. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.01.1680 · Cited by 11
Self-citation
Metadata
- Authors
- Kishi, T., Sakuma, K., Hatano, M., Okuya, M., Matsuda, Y., Kato, M., & Iwata, N.
- Affiliations
- Fujita Health University (JP)
- Jikei University School of Medicine (JP)
- Kansai Medical University (JP)
- Corresponding author
- Kishi, Taro
- Venue
- Molecular Psychiatry
- Published
- 2022-12-23
- Volume
- 28
- Issue
- 3
- Pages
- 974-976
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC10005929
- OpenAlex
- W4312129775
- Cited by
- 26
- References
- 6
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 8
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Grant-in-Aid for Young Scientists
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- major depressive disorder, antidepressant discontinuation, relapse, antidepressant maintenance, relapse prevention, remission, open-label extension
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Recurrence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. https://app.cochat.ai/papers/10.1038/s41380-022-01920-0
- The paper
- Kishi, T., Sakuma, K., Hatano, M., Okuya, M., Matsuda, Y., Kato, M., & Iwata, N. (2023). Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01920-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.